MNMD241220P17000
- 8.98
- 0.000.00%
Mind Medicine Newsroom
RBC Capital Maintains Mind Medicine(MNMD.US) With Buy Rating, Maintains Target Price $21
RBC Capital Remains a Buy on Mind Medicine (MNMD)
Mind Medicine Appoints Gregg Pratt Chief Regulatory, Quality Assurance Officer
Is Mind Medicine (MNMD) the Best Multibagger Stock to Buy Heading Into 2025?
RFK and the 'MAHA Trade': Vaccine Makers Down, Psychedelic Shares up
Mind Medicine (MindMed) Inc.'s (NASDAQ:MNMD) Market Cap Touched US$601m Last Week, Benefiting Both Retail Investors Who Own 41% as Well as Institutions
AI And Psychedelics: A Marriage Made In Heaven For Mental Health Care?
MindMed to Participate in Upcoming Investor Conferences
Express News | Mind Medicine Shares Are Trading Higher. HC Wainwright & Co. Reiterated a Buy Rating on the Stock
Mind Medicine Analyst Ratings
Optimistic Outlook for Mind Medicine Amidst Promising Phase 3 Developments and Robust Financial Health
Maxim Group Maintains Mind Medicine(MNMD.US) With Buy Rating, Maintains Target Price $18
Oppenheimer Maintains Mind Medicine(MNMD.US) With Buy Rating, Maintains Target Price $20
H.C. Wainwright Maintains Mind Medicine(MNMD.US) With Buy Rating, Maintains Target Price $55
Express News | Mind Medicine Shares Are Trading Higher After the Company Reported Better-than-expected Q3 EPS Results
Mind Medicine's Strategic Advancements and Clinical Progress Drive Buy Rating
CCORF Maintains Mind Medicine(MNMD.US) With Buy Rating, Raises Target Price to $16
RBC Capital Maintains Mind Medicine(MNMD.US) With Buy Rating, Cuts Target Price to $21
RBC Capital Keeps Their Buy Rating on Mind Medicine (MNMD)
Analysts Offer Insights on Healthcare Companies: Mind Medicine (MNMD), Knight Therapeutics (OtherKHTRF) and OnKure Therapeutics (OKUR)